HC Wainwright Reaffirms “Buy” Rating for Dianthus Therapeutics (NASDAQ:DNTH)

HC Wainwright reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock.

DNTH has been the topic of a number of other research reports. Oppenheimer increased their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday. Wedbush cut their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Raymond James lifted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target on the stock. Finally, Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $26.35 on Monday. The company’s 50-day moving average is $27.70 and its 200-day moving average is $26.64. The firm has a market capitalization of $779.88 million, a PE ratio of -10.54 and a beta of 1.84. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, analysts expect that Dianthus Therapeutics will post -2.52 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the period. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth $236,000. WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics in the second quarter worth $265,000. Finally, Point72 DIFC Ltd acquired a new position in Dianthus Therapeutics in the second quarter valued at about $334,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.